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Dorothy Hodgkin solved the crystal structure for porcine 
insulin in 1969, work that paved the way for the develop-
ment of human and analogue insulins that have trans-
formed care for patients with insulin- treated diabetes. At 
this time, there were two classes of drugs used to treat dia-
betes: biguanides and sulphonylureas. Both the biguanide, 
metformin,1 and sulphonylureas2 were introduced into 
clinical practice in the 1950s and were the only diabetes 
treatment other than insulin until the 1990s – when acar-
bose (1995), miglitol (1996), troglitazone (1996) and 
repaglinide (1997) were approved.3 In the last 6 years, sev-
eral large randomised controlled trials have established the 
beneficial cardiovascular (CV) and renal effects of two of 
the newer classes of agent – Sodium Glucose Transporter 
2 inhibitors (SGLT2i) (2012) and Glucagon- like Peptide 1 
Receptor Agonists (GLP- 1RA) (2005) – and these are now 
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Abstract
Glycaemic response to metformin and sulphonylureas is heritable – with ~34%– 
37% of variation explainable by common genetic variation. The premise of this re-
view is that by understanding how genetic variation contributes to drug response 
we can gain insights into the mechanisms of action of diabetes drugs. Here, I focus 
on two old drugs, metformin and sulphonylureas, where I would suggest we still 
have a lot to learn about their mechanism of action or their optimal use in clinical 
care. The fact that reduced function variants of the key transporter that takes met-
formin into the liver (OCT1) do not alter glycaemic response to metformin suggests 
that metformin does not need to get into the liver to work. A subsequent GWAS 
of metformin response identifies a robust variant that alters GLUT2 expression – 
which may support increasing evidence that metformin works primarily in the gut. 
For sulphonylureas, observation from patients with neonatal diabetes due to acti-
vating KATP channel mutations treated with sulphonylureas identified a novel role 
for sulphonylureas to enable β- cell incretin response. This work led to recent stud-
ies of low- dose sulphonylurea (20 mg gliclazide) in T2DM, which identified that 
at this dose sulphonylureas augment the incretin effect and increase β- cell glucose 
sensitivity, without increasing hypoglycaemia risk. This work, prompted by studies 
in monogenic diabetes, suggests that we have historically been using sulphony-
lureas at too high a dose. With increasing availability of genetic data pharmacog-
enomic studies in patients with diabetes should reveal mechanistic insights into old 
and new diabetes drugs, with the potential for optimized use and novel therapies.
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indicated second line after metformin in those at high 
CV risk or with chronic kidney disease.4 Yet more than 
60 years after their introduction, metformin remains the 
most widely used diabetes treatment, and sulphonylureas 
are still used extensively.5 For both metformin and sul-
phonylureas the glucose- lowering effect was an incidental 
finding; the drugs were not designed to inhibit or activate 
a particular receptor or transporter. Whilst sulphonylureas 
have subsequently been shown to have a largely targeted 
mechanism – inhibition of the β- cell KATP channel – the 
molecular targets of metformin remain uncertain. In this 
review, I will revisit these two stalwarts of diabetes ther-
apy, highlighting how we can gain insights from human 
genetics into the molecular and physiological mechanisms 
of action of metformin and sulphonylureas.
Patients treated with glucose- lowering treatment 
vary in their response – some gain considerable benefit, 
whereas others have no benefit; some get limiting side ef-
fects, but many do not. There are many factors that impact 
on this variation, but we know this is a heritable trait (i.e. 
some of the variation is genetic): the SNP- based herita-
bility for glycaemic response to metformin is 34%,6 with 
similar estimates for sulphonylureas (37%, Diabetes Care 
in press). For comparison, the SNP- based heritability of 
height, a highly heritable trait, is ~55%. Thus, the study of 
pharmacogenomics, that is, how this genetic variation im-
pacts on drug efficacy, has the potential to provide a tool 
to investigate the biological mechanisms of drug action. 
Diabetes pharmacogenomics can be approached from two 
directions. The first approach considers genetic variation 
that alters diabetes risk, on the assumption that the ge-
netic processes whereby someone develops diabetes may 
alter how they respond to a diabetes drug. This can be seen 
in the extreme example of HNF1A MODY – the mono-
genic defect that causes diabetes impacts on β- cell mecha-
nisms in such a way as to make patients with this diabetes 
exquisitely sensitive to sulphonylureas,7,8 or in neonatal 
diabetes (NDM) as will be discussed later with respect 
to sulphonylureas. The second approach is to consider a 
drug intervention as an exposure and address how patient 
genotype alters response to diabetes treatment – this may 
identify not only the aetiological variation but also the 
mechanisms of drug action that are independent of aeti-
ology. I will expand upon this approach when considering 
genetic insights into metformin response.
1  |  INSIGHTS FROM GENETICS: 
HOW DOES METFORMIN WORK TO 
LOWER GLUCOSE?
Metformin is a potent glucose- lowering agent, that has 
many potential non- glucose benefits – reviewed in a 
series of linked articles released to celebrate 60  years of 
metformin.9,10 The mechanisms of action for metformin 
in glucose lowering are much debated and a detailed dis-
cussion is beyond the scope of this review; for more detail 
see Reference [11].Metformin is absorbed from the gut 
(where it is the most highly concentrated compared with 
any other tissue due to active transport by a range of or-
ganic cation transporters); it is actively transported into 
the liver, before being taken up and excreted via the kid-
neys. Concentrations of metformin outside of these three 
tissues are very low and as such it seems likely that met-
formin lowers glucose by acting at the gut, liver or kidneys 
(or a combination of these tissues).
Human genetic variation provides a useful tool to in-
vestigate the site of metformin action. A widely proposed 
mechanism of action for metformin is that it acts on the 
liver to lower hepatic glucose output.12 Metformin is a cat-
ion and as such is actively transported into tissues, with 
minimal passive diffusion. The main transporter taking 
metformin into the liver is OCT113 – encoded by SCL22A1. 
In European ethnic populations, two genetic variants that 
reduce OCT1 function are relatively common (rs72552763, 
M420Del, MAF (minor allele frequency) 19%; rs12208357, 
R61C, MAF 6%). A recent paper using 11C- metformin and 
PET/CT imaging established that carriage of either the 
420del or 61C variant reduced metformin uptake into the 
liver in humans (Figure 1).14 Given this, we hypothesised 
that if metformin lowers glucose by acting on the liver, then 
patients carrying reduced function OCT1 variants should 
not respond so well to metformin treatment as those with 
normal function (wildtype) OCT1. We first undertook a 
study in a Scottish cohort (Genetics of Diabetes Audit and 
Research Tayside Scotland; GoDARTS) in ~1500 patients 
with type 2 diabetes treated with metformin,15 and then 
in a larger Metformin genetics consortium (MetGen) co-
hort of ~4500 patients16 and showed no effect of carriage 
of either the 420del or the 61C variant of OCT1; the point 
estimate when looking at the variants in combination was 
slightly in favour of metformin benefit in these patients 
(Figure 2). This genetic data would suggest that metformin 
does not need to enter the liver to lower glucose in patients 
with diabetes, and is supported by recent tracer studies in 
patients with recent onset T2D17 or those without diabe-
tes18,19 that metformin treatment results in an increase in 
hepatic glucose production rather than a reduction, likely 
secondary to an increase in glucose clearance.
An alternative approach to use human genetics to gain 
insight into metformin action is to utilise a genome- wide 
association study (GWAS). This tests ~3  M variants dis-
tributed across the genome to see if any variants are asso-
ciated with altered glycaemic response to metformin, and 
as such makes no prior assumption about the biological 
mechanism. In the largest GWAS of glycaemic response 
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to metformin to date, the MetGen consortium reported a 
large, robust signal at an intronic locus within SLC2A2, 
encoding the glucose transporter GLUT2.20 In this study 
we show that C- allele rs8192675 is associated with a 
greater glycaemic response to Metformin – with those 
with a CC genotype having a 4 mmol/mol (0.4%) greater 
HbA1c reduction than those with a TT genotype (a dose 
equivalence of 550 mg metformin). We also show that this 
C- allele is associated with reduced GLUT2 expression in 
the liver and intestines. What does this tell us about how 
metformin is working and at what site? GLUT2 is an im-
portant glucose transporter in the liver, enabling bidirec-
tional glucose flux in the fasting and prandial state, with 
deletion of glut2 reducing glucose uptake but not output 
by the liver.21 However, our prior genetic data does not sup-
port an important role for metformin in the liver. GLUT2 
is similarly a facilitative glucose transporter expressed in 
the basolateral membrane of intestinal enterocytes. Mice 
lacking GLUT2 do not have altered absorption of glucose 
following oral ingestion21; however, metformin increases 
uptake of glucose into enterocytes from the systemic cir-
culation (across the basolateral membrane) rather than 
the lumen,22 probably explaining the increase in glucose 
clearance observed in the tracer studies described above. 
We hypothesise that intestinal GLUT2 may be in part mod-
erating metformin efficacy, although exactly how remains 
an important question. At the time of writing, colleagues 
in Dundee and Turku are undertaking studies on met-
formin treatment in mice with heterozygous glut2 knock 
out, and with intestinal specific glut2 knockout aiming to 
address this hypothesis.
2  |  INSIGHTS FROM GENETICS: 
HOW DO SULPHONYLUREAS 
WORK? ARE WE USING THEM 
CORRECTLY?
Sulphonylureas were discovered in 1942 as severe hy-
poglycaemia was identified in patients treated with sul-
phonamides, used to treat typhoid fever. With clinical 
introduction in the 1950s, it was not until 1985 that the β- 
cell KATP channel was identified as the likely target of sul-
phonylureas.23 Subsequently the mechanisms mediating 
this via binding of sulphonylureas to the SUR1 subunit of 
the KATP channel have been extensively characterised and 
are reviewed elsewhere (e.g. see Ref. [24– 26]).
It is necessary here to briefly review the physiology of 
glucose- stimulated insulin secretion by the pancreatic β- 
cell. Two important pathways are recognised, as described 
by Henquin27 – the triggering pathway and the amplifying 
F I G U R E  1  Hepatic metformin exposure after oral ingestion of 
11C- Metformin. Summed 11C- metformin PET images from a person 
wildtype for SLC22A1 genotype (a) and a person with two reduced 
function variants of SLC22A1 (b). The uptake into the liver seen in 
(a) is markedly attenuated in (b). Reproduced with permission from 
Reference [14]
F I G U R E  2  Forrest plot representing the association of carriage 
of one or more reduced function OCT1 variants (R61C, M420del) 
on glycaemic response to metformin. Data are shown for individual 
cohorts (DCS, GoDARTS, PMT1- EU, PMT2- EU, Sarajevo) along 
with an overall effect following meta- analysis. A positive result 
represents better glycaemic response to metformin. Modified from 
Reference [16]
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pathways. The triggering pathway is mediated via the KATP 
channel, closure of which results in a rise in membrane 
potential sufficient to trigger calcium influx and insulin 
secretion. Insulin secretion is amplified by glucose, incre-
tins, charged amino acids and other nutrients. The am-
plifying pathways are only evident when the triggering 
pathway is active – as when the KATP channel is not closed 
the large potassium currents dominate, and the other 
mechanisms have little effect. Sulphonylurea binding to 
SUR1 brings about closure of the KATP channel indepen-
dent of glucose metabolism and triggers insulin secretion. 
Importantly, at the doses used to treat patients with T2D, 
closure of the KATP channel results in triggering of insulin 
secretion even when the blood glucose is low, resulting in 
increased risk of hypoglycaemia. Figure 3a shows a sche-
matic representation of insulin secretion against glucose 
for patients with T2D treated with sulphonylureas. At a 
given glucose concentration there is an increase in insulin 
secretion. Note that there is an increase in the slope (the 
glucose sensitivity) as once triggered by KATP channel clo-
sure the amplifying mechanisms, including glucose, can 
operate to increase insulin secretion, and sulphonylureas 
are reported to act via a non- KATP mechanism to augment 
the amplifying pathway.28 The ideal secretagogue would 
increase β- cell glucose sensitivity while maintaining glu-
cose dependency so when the glucose concentrations 
drop below 4 mmol/L there is no insulin secretion. This is 
shown schematically in Figure 3b and is seen with drugs 
that act via the incretin system, for example, DPP- 4 inhib-
itors and GLP- 1RA.
The human genetic insights into the mechanism 
of action of sulphonylureas come from patients with 
NDM due to activating mutations in either the KCNJ1129 
or ABCC830  genes, encoding the Kir6.2 and SUR1 
components of the KATP channels. These patients develop 
insulin- requiring diabetes often with ketoacidosis in the 
early neonatal period (up to 6 months of age). Following 
the discovery of the genetic aetiology in these patients, 
we established that patients who had been on lifelong 
insulin treatment were able to successfully transition off 
insulin on to (high- dose) oral sulphonylurea treatment.31 
Many patients with NDM treated with sulphonylureas 
can achieve near normalisation of their glucose, with 
HbA1c in the non- diabetic range, yet have little to no hy-
poglycaemia. Physiological studies undertaken before and 
after transition to sulphonylureas are striking (Figure 4). 
Before treatment with sulphonylureas, there is no insulin 
secretion in response to intravenous (iv) or oral glucose. In 
patients treated with sulphonylureas, there is a small mea-
surable insulin secretory response to IV glucose, yet there 
is a large insulin secretory response to oral glucose. This 
greater insulin secretion with oral versus iv glucose is a 
measure of the incretin effect – in patients with NDM due 
to KATP channel mutations, sulphonylureas are enabling 
the β- cell to respond to incretins (amplifying pathway) 
with minimal effect on the direct (triggering) pathway. So, 
for these patients, in contrast to that seen in T2DM, sul-
phonylureas are acting as the perfect secretagogue.
How can sulphonylureas promote meal- regulated in-
sulin secretion in patients with NDM? Elegant work from 
Fran Ashcroft's lab provides a clue to this. They studied 
isolated β- cells from mice with the V59M mutation in 
Kir6.2 and compared with wildtype mice.32 In whole- cell 
patch clamp studies, glibenclamide resulted in a rapid 
and near complete reduction in membrane conductance 
in normal (wildtype) β- cells. By contrast, in β- cells from 
mice carrying the V59M mutation, higher doses of glib-
enclamide were needed to reduce the conductance, and 
F I G U R E  3  A schematic representation of insulin secretion against glucose. (a) shows the effect of sulphonylureas – an increase in 
insulin secretion even at low glucose and a probable increase in glucose sensitivity (the slope). (b) shows the ideal secretagogue – an increase 
in the slope, but with no increased insulin secretion below a glucose of 4 mmol/L. The blue lines are without secretagogue, the red lines are 
with secretagogue
(a) (b)
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even with very high concentrations there was never com-
plete closure of the KATP channels (i.e. conductance did 
not reduce to zero). It is this latter property that probably 
means that patients do not develop hypoglycaemia despite 
high doses of SU. The residual KATP conductance in the 
presence of SU holds the pancreatic β- cell at a subthresh-
old voltage insufficient to trigger insulin secretion directly, 
thus minimising hypoglycaemia, but at a level where only 
small changes in non- KATP conductance can trigger insu-
lin release, resulting in postprandial insulin secretion.
Given that patients with NDM on high- dose SU with 
normal HbA1c are able to fast for 24 h without hypoglycae-
mia, is it possible for this effect to be mimicked in T2DM? 
The key question here is whether, in the context of only 
mildly impaired KATP channel function, it is possible to 
use a low enough dose of SU to partially lower KATP con-
ductance to a similar level as seen in NDM and high- dose 
SU. To address this question, we have recently undertaken 
a series of studies of low- dose SU in patients with T2DM. 
The usual starting dose of gliclazide is 40– 80 mg; after an 
initial dose ranging study, we used 20 mg. We first investi-
gated the effect of low- dose gliclazide on β- cell physiology 
and specifically on the incretin effect.33 To assess the in-
cretin effect, we undertook ‘isoglycaemic clamp’ studies. 
In these, a paired oral glucose tolerance test and isoglycae-
mic iv glucose infusion are given on different days – with 
the difference in insulin secretion between the iv and oral 
stimulus reflecting the gut secreted incretins. We showed 
that the incretin effect is increased from 35.5% to 55% 
(p = 0.049) by 20 mg oral gliclazide. Interestingly, when 
we plot the insulin concentration for a given glucose in 
response to oral and iv glucose (Figure 5), there is min-
imal augmentation of insulin secretion with sulphony-
lurea treatment for an iv glucose stimulus, but in response 
to an oral glucose stimulus, 20  mg gliclazide augments 
insulin secretion by augmentation of the slope (glucose 
sensitivity) but with no direct effect at low glucose levels 
– in other words, at a dose of 20 mg gliclazide can act as 
the ideal secretagogue (Figure 3b). In a second study we 
have undertaken a crossover trial of placebo, 20  mg of 
F I G U R E  4  Physiological studies in patients with neonatal diabetes due to activating KCNJ11 mutations. The left panel shows the 
plasma insulin concentrations over 10 min after an iv glucose bolus in patients before being treated with sulphonylureas (dashed line) and 
after transitioning onto sulphonylurea treatment (solid line). The right panel shows the insulin concentrations over 120 min after an oral 
glucose challenge in patients before (dashed line) and after (solid line) transition to sulphonylurea treatment. Reproduced with permission 
from Reference [31]
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F I G U R E  5  Effects of low- dose (20 mg) gliclazide in patients with T2DM. The left panel shows the insulin secretion plotted against 
glucose following oral glucose challenge with (blue) and without (red) gliclazide; the right panel shows the insulin secretion plotted against 
glucose following an isoglycaemic intravenous glucose with (blue) and without (red) gliclazide. Reproduced with permission from Reference 
[33]
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gliclazide, 100  mg of sitagliptin and the combination of 
low- dose gliclazide and sitagliptin, undertaking mixed- 
meal tolerance tests on each arm. This ‘Sulphonylureas 
synergistic with sitagliptin study’ (SSS) (NCT04192292) 
investigated the glucose- lowering effect at mixed meal, 
as well as undertaking continuous glucose monitoring to 
look for evidence of hypoglycaemia, aiming to establish 
the efficacy of low- dose gliclazide relative to sitagliptin, 
and to investigate if low- dose gliclazide, that increases the 
incretin effect, works synergistically with DPP- 4i, that in-
crease circulating endogenous incretins. This trial will be 
reported separately to this review.
To conclude, using human monogenic diabetes an 
exemplar, we have established that sulphonylureas used 
at high dose in NDM are highly effective largely by en-
abling the β- cell to respond to non- glucose stimuli and 
do not cause hypoglycaemia as the mutant channels can-
not fully close. Leading directly from these observations 
we have now established that 20 mg of gliclazide works, 
at least in part, by augmenting the incretin effect and at 
this dose are potent and do not cause hypoglycaemia. 
Sulphonylureas are dropping out of current guidelines, 
with the latest ADA/EASD guidelines relegating them 
to ‘where cost is an issue’. The main concerns with sul-
phonylureas are weight gain, hypoglycaemia, reduced 
durability and lack of CV benefit. I believe that the first 
three of these concerns reflect the doses and types of 
sulphonylureas used (see Ref. [2]). Low- dose gliclazide 
should cause minimal weight gain and no hypoglycae-
mia due to the greater role of the incretin effect at these 
doses, and there should be no persistent β- cell hyperpo-
larisation that causes loss of β- cell function (at least in 
mice34) and reduced durability of action. In short, we 
have historically been using sulphonylureas at far too 
high a dose and need to revisit how this cheap effective 
drug is used.
3  |  INSIGHTS INTO MECHANISMS 
OF DRUG ACTION: NEWER AGENTS
What about the newer diabetes treatments like GLP- 1RA or 
SGLT2i – can we learn from human genetics? We already 
have – genetics tells us that people with genetic loss of 
SGLT2i are healthy35 and thus SGLT2i inhibitors should be 
safe, and that variants in GLP- 1R that lower glucose and re-
duce diabetes risk and thus mimic GLP- 1RA, have reduced 
CV risk.36 But what about variability in response to these 
drugs? Why do some people have weight loss and minimal 
glucose lowering with GLP- 1RA, or glucose lowering with 
minimal weight loss? What is the mechanism whereby 
SGLT2i reduce risk of heart failure or decline in renal 
function? With large, well- powered GWAS of glycaemic 
response, weight change and CV outcome I hope that 
human genetics will contribute to our understanding of the 
mechanisms of action for these drugs too in the near future.
4  |  CONCLUSIONS
Identifying how genetic variation alters the response 
to the treatment serves two purposes – firstly, it may 
provide novel insights into drug mechanisms, that may 
not be apparent from studying drug action in vitro or in 
animal models; secondly, it may enable a targeted treat-
ment approach in the clinic. This second aspect is ad-
dressed elsewhere37 – but in brief, yes, I strongly believe 
that within 10 years genotyping will be embedded in the 
medical record and the size of genetic effects identified 
to date will inform on treatment decisions. In this re-
view, given the basic science focus of the Diabetes UK 
Dorothy Hodgkin Lecture, I have focused on the role 
of human pharmacogenomics to provide insight into 
drug mechanism as I think this is an exciting and un-
recognised potential for pharmacogenomics. With in-
creasing availability of genetic data in large populations 
(e.g. UKBiobank, Our Future Health) and an increas-
ing openness by industry to undertake and share ge-
netic analyses of clinical trials, studying genetic impact 
on drug outcome and undertaking recruit by genotype 
physiological studies will provide a much deeper under-
standing of how the available diabetes drugs work, po-
tentially enabling optimized use and a route to develop 
novel therapies.
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